MNPR Stock Rallies After Hours As Experimental Drug Shows Rapid Copper Balance Improvement In Genetic Disorder

• Last week, the company said that it plans to file a New Drug Application with the U.S. Food and Drug Administration in mid-2026 for ALXN1840 in the treatment of Wilson disease.
• Wilson disease is a rare genetic disorder that causes dangerous copper buildup in the liver, brain, and other organs.
• Monopar also noted it has enough cash to fund operations through at least the end of 2027.

Shares of Monopar Therapeutics (MNPR) edged up 3% after hours on Tuesday after the company’s experimental drug ALXN1840 significantly improved copper balance in patients with Wilson disease in a mid-stage clinical study.  

The open-label trial showed the drug helped the body remove excess copper more effectively and quickly, mainly by increasing copper excretion through stool. Patients in the study had already been on standard treatments for an average of 16 years, yet ALXN1840 still delivered a rapid and sustained benefit, the company said, while adding that the drug was also well tolerated with no serious adverse events. The results were consistent with positive data from the company’s late-stage trial where ALXN1840 demonstrated superior copper mobilization compared to standard of care.  

MNPR’s Plans Ahead

Wilson disease is a rare genetic disorder that causes dangerous copper buildup in the liver, brain, and other organs. Current treatments can have side effects or limited results for some patients. Monopar is developing ALXN1840 as a potential alternative.  

Last week, the company said that it plans to file a New Drug Application with the U.S. Food and Drug Administration in mid-2026 for ALXN1840 in the treatment of Wilson disease. The firm also said that it is leading commercial readiness activities as it gears up for a potential launch.

Monopar also noted it has enough cash to fund operations through at least the end of 2027.  

How Did MNPR Retail Traders React?

On Stocktwits, retail sentiment around MNPR stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.

MNPR stock has risen about 50% over the past 12 months. 

Read More: RBLX Stock Edges Up After Hours As $3B Buyback Eases Post-Guidance Jitters

For updates and corrections, email newsroom[at]stocktwits[dot]com.